Tests PF-08634404 with chemotherapy in extensive-stage small cell lung cancer
Tests a new medicine with chemotherapy in adults with widespread small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Key facts
- Where
- Duesseldorf and Frankfurt am Main, GermanySee the 2 sites
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive-stage small cell lung cancer who have not yet had treatment for it. It tests PF-08634404 given with chemotherapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Extensive-stage small cell lung cancer confirmed by lab tests, with at least one measurable tumour spot (RECIST V1.1). Daily activity level (ECOG) of 0 or 1.
- Earlier treatment
- No earlier systemic treatment (chemotherapy, radiotherapy, chemoradiation) for extensive-stage disease. People treated for limited-stage disease must be treatment-free for at least 6 months.
Main reasons for not taking part
- Known active spread to the brain or spinal cord, including brainstem or meninges
- Leptomeningeal disease
- Clinically significant risk of bleeding or fistula
- Another cancer within the past 3 years
- Active autoimmune disease needing systemic treatment within the past 2 years
Read by machine on 9 November 2026.
Where in Germany
- Marien Hospital Duesseldorf GmbHDuesseldorf, GermanyNot yet recruiting
- Krankenhaus Nordwest GmbHFrankfurt am Main, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07226999EU 2025-523522-41-00
- Record updated
- 8 October 2026
- Original description
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body.Read full original descriptionShow less
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body.
To join the study, participants must meet the following conditions:
* Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
* In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better.
Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.
Inclusion: Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC); Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC; Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC; Have at least one measurable lesion as the targeted lesion based on RECIST V1.1; Eastern Cooperative Oncology Group performance status of 0 or 1; Adequate organ function.
Exclusion: Leptomeningeal disease; Clinically significant risk of hemorrhage or fistula; history of another malignancy within 3 years; active autoimmune diseases requiring systemic treatment within the past 2 years; known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression.